Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have ≤35 μg due to increased risks of cardiovascular diseases (CVD) with higher doses of EE. Low‐dose formulations however, have resulted in increased incidences of breakthrough bleeding and contraceptive fai...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Pharmacol Ther
Asıl Yazarlar: Ezuruike, Udoamaka, Humphries, Helen, Dickins, Maurice, Neuhoff, Sibylle, Gardner, Iain, Rowland Yeo, Karen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6282492/
https://ncbi.nlm.nih.gov/pubmed/29637542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1085
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller